

# Enhanced *in vitro* invasiveness of ovarian cancer cells through up-regulation of VEGF and induction of MMP-2

ALI ZHANG<sup>1\*</sup>, LI MENG<sup>1\*</sup>, QUNSHENG WANG<sup>2</sup>, LING XI<sup>1</sup>, GANG CHEN<sup>1</sup>, SHIXUAN WANG<sup>1</sup>,  
JIANFENG ZHOU<sup>1</sup>, YUNPING LU<sup>1</sup> and DING MA<sup>1</sup>

<sup>1</sup>Cancer Biology Center, Tongji Hospital; <sup>2</sup>Department of Nephrology, Xiehe Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China

Received November 1, 2005; Accepted January 3, 2006

**Abstract.** Vascular endothelial growth factor (VEGF) has been identified to be important in tumor angiogenesis, which is essential for the growth, invasion, and metastasis of solid tumors. The aim of this study was to determine the effect of VEGF overexpression on the invasion of human epithelial ovarian cancer cells *in vitro* and the possible mechanism involved. The VEGF<sub>165</sub> cDNA was transfected into ovarian tumor cell lines CAOV3 and COC1 to promote the expression of VEGF. The VEGF expression and matrix metalloproteinase (MMP)-2 activity were examined by RT-PCR, Western blot analysis and gelatin zymography. A modified Boyden chamber assay was used to test tumor cell invasion *in vitro*. All cells overexpressing VEGF displayed an enhanced *in vitro* invasiveness through Matrigel-coated filters with Boyden chamber invasion assay. MMP-2 mRNA and protein were significantly increased during VEGF<sub>165</sub> cDNA transfection; MMP-2 activity was also increased. The invasion property of ovarian cancer cells was abrogated with VEGF neutralizing antibody. Our data indicated that the expression of VEGF gave impetus to the *in vitro* invasion of ovarian cancer cells by stimulating the production and functional activities of MMP-2, which may be a key component of VEGF in promoting ovarian cancer cell invasion. VEGF may constitute a novel therapeutic target for antiangiogenic cancer therapy.

## Introduction

Epithelial ovarian carcinoma is the leading cause of death from gynecologic malignancy and causes 100,000 deaths annually in women worldwide. Additionally, most patients have disseminated intraperitoneal spread at the time of diagnosis, and approximately 40% of women with advanced ovarian cancer have lymph node metastasis. However, the mechanism of metastasis remains unclear.

VEGF is a multifunctional peptide that elicits numerous cellular effects pertinent to the metastasis process including the regulation of epithelial cell proliferation, modulation of angiogenesis, and synthesis of extracellular matrix proteins (matrix metalloproteinases, MMPs). The expression of VEGF has been reported to correlate with the malignancy of different tumor types, such as gliomas, prostate cancer, pancreatic adenocarcinoma, renal cell carcinoma, squamous cell carcinomas, bladder cancer, non-small cell lung cancer, hepatic carcinoma and colorectal cancer (1-4). Recent studies have shown that the elevated serum VEGF levels and increased VEGF expression in epithelial ovarian tumor were associated with the development, invasion and metastasis of ovarian tumors (5,6). VEGF<sub>165</sub> overexpression stimulated angiogenesis and induced cyst formation and macrophage infiltration in human ovarian cancer engrafts (7). However, there have been no direct studies showing that the overexpression of VEGF promotes ovarian tumor metastasis.

Tumor metastasis requires that tumor cells first attach to the extracellular matrix through cell membrane receptors that mediate binding to matrix components, such as laminin, collagen and fibronectin. Subsequently, localized proteolysis initiated by tumor cells results in the degradation of matrix (8). Two families of proteases, the plasminogen activator/plasmin system of serine proteases and MMPs, have been implicated in these processes (9). Ovarian cancer cells express MMP-2 and MMP-9, and their increased expression is associated with their invasive and metastatic potential (10-13). Furthermore, treatment administered to animals harboring ovarian cancer xenografts with synthetic MMP inhibitors reduced the tumor burden (14). It has been shown that stromal MMP-9 contributes to the malignant behavior of ovarian cancers by promoting neovessel sprouting and tumor growth (15), and the fact that accelerated SMC migration treated by VEGF could be blocked by MMP inhibition in

---

Correspondence to: Dr Ding Ma, Cancer Biology Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, Hubei 430030, P.R. China  
E-mail: dma@tjh.tjmu.edu.cn

\*Contributed equally

**Abbreviations:** VEGF, vascular endothelial growth factor; MMPs, matrix metalloproteinases

**Key words:** ovarian carcinoma, vascular endothelial growth factor, matrix metalloproteinase, invasion

Matrigel indicated that MMPs may contribute to SMC migration in angiogenesis (16). Further results showed that minocycline inhibited VEGF-induced smooth muscle cell migration, including inhibition of MMP-9 mRNA transcription and protein activities, and down-regulating ERK1/2 and PI3K signaling pathways (17). These findings suggest an interplay between VEGF and MMP-9. However, scarce data are available on the potential relationship between VEGF and MMP-2 in the invasion of ovarian cancer.

In the present study, we investigated the correlation between VEGF and MMP-2 and evaluated their potential effects on the invasion capacity of ovarian tumor cell lines *in vitro* to clarify the role of VEGF in metastasis and the underlying mechanism.

## Materials and methods

**Cell culture and reagents.** The epithelial ovarian cancer cell lines CaOV3 and COC1, obtained from the American Type Culture Collection, were grown in DMEM or RPMI-1640 with 10% heat-inactivated fetal bovine serum and penicillin-streptomycin (50 units/ml-50  $\mu$ g/ml). NIH 3T3 cells, kindly provided by Dr Lijun Xin (Center of Immunology, Wuhan, China), were cultured in RPMI-1640 with 10% heat-inactivated fetal bovine serum and penicillin-streptomycin. Cells were grown at 37°C in a humidified atmosphere (5% CO<sub>2</sub>, 95% air).

VEGF<sub>165</sub> cDNA was a generous gift from Dr Jianguo Ma (Fox Chase Cancer Center, USA). Trizol reagent was purchased from Gibco. Dosper liposomal transfection reagent was obtained from Boehringer-Mannheim. Oligonucleotides were acquired from Shenggong Biotechnology (Shanghai, China). Anti-MMP-2 goat IgG and anti-VEGF rabbit IgG were purchased from Santa Cruz Biotechnology. Rabbit anti-goat IgG and goat anti-rabbit alkaline phosphatase conjugate were obtained from Zhongshan Biotechnology (Beijing, China). Growth factor-reduced Matrigel was purchased from Becton-Dickinson. The 8  $\mu$ m-pore PET membrane and 48-well invasion plates were provided by Professor Feili Gong (Center of Immunology, Wuhan, China). Cell culture reagents and other chemical materials were purchased from Sigma.

**Transfection of tumor cells with VEGF<sub>165</sub> cDNA.** Bacteria DH5 $\alpha$  transformed with VEGF<sub>165</sub> cDNA were amplified, and the plasmid VEGF<sub>165</sub> cDNA was prepared and purified according to the Molecular Cloning: A Laboratory Manual. The prepared plasmid was digested with restriction enzyme *Bam*HI, *Eco*RI at 37°C for 2 h, then electrophoresis was performed. Ovarian tumor cells were transfected using Dosper Liposomal Transfection Reagent according to the manufacturer's instructions. PcDNA3.1 vector was transfected as an empty vector control.

**Preparation of conditioned media.** Conditioned media were prepared by incubating subconfluent cells in 24-well plates for 24 h in serum-free DMEM or RPMI-1640. Cells were trypsinized and counted. Conditioned media were harvested and clarified by centrifugation, and stored at -80°C.

**RT-PCR VEGF and MMP-2.** Total RNA was extracted from the cell monolayer using the Trizol reagent kit following the




Figure 1. RT-PCR and Western blot analysis of VEGF expression in ovarian cancer cells, transfected with either VEGF<sub>165</sub> cDNA or empty vector PcDNA3.1 mRNA of ovarian cancer cells CaOV3 and COC1, were acquired and then demonstrated by RT-PCR using primers specific for VEGF and  $\beta$ -actin (A). Whole cell lysates were detected by Western blot analysis with specific antibodies against VEGF or  $\beta$ -actin (B).

manufacturer's instructions. For reverse transcription (RT)-PCR analyses, 2  $\mu$ g RNA was treated with RNase-free DNase, and cDNA was obtained using Moloney murine leukemia virus reverse transcriptase. For semiquantitative PCR, 5  $\mu$ l cDNA was amplified by PCR using the specific primers: VEGF (18) (454 bp), 5'-GGA TGT CTA TCA GCG CAG CAC -3' and 5'-TCA CCG CCT CGG CTT GTC ACA TC-3'; MMP-2 (19) (580 bp), 5'-GTG CTG AAG GAC ACA CTA AAG AAG A-3' and 5'-TTG CCA TCC TTC TCA AAG TTG TAG G-3';  $\beta$ -actin (20) (266 bp), 5'-AGC AGA GAA TGG AAA GTC AAA-3' and 5'-ATG CTG CTT ACA TGT CTC GAT-3'. PCR conditions were followed by 30 cycles for VEGF or MMP-2 consisting of 94°C for 1 min, 61°C for 2 min, 72°C for 2 min or 94°C for 45 sec, 59°C for 1 min and 72°C for 90 sec, and a final elongation step of 72°C for 5 min. The reaction products were visualized by subjecting them to electrophoresis in 1.5% agarose in 1X TBE buffer containing 0.5  $\mu$ g/ml ethidium bromide.

**Western blot analysis.** Aliquots of the conditioned media adjusted to the same number of cells were boiled for 5 min in sample buffer. Proteins were resolved by electrophoresis in 10% sodium dodecyl sulfate-polyacrylamide gels (SDS-PAGE) and transferred to nitrocellulose membranes. The membranes were incubated in blocking solution containing 5% nonfat dry milk and 0.05% Tween-20 in TBS (TBS-T) at room temperature for 1 h to inhibit nonspecific binding. The membranes were then incubated with the primary antibody [anti-VEGF polyclonal IgG (1:1000) and anti-MMP-2 polyclonal IgG (1:1000)] at 4°C overnight. After 3 washes with TBS-T, the membrane was incubated with alkaline phosphatase-conjugated secondary antibody at 37°C for 1 h. NBT/BCIP was used to detect the hybridization protein.

**Gelatin zymography.** Aliquots (5-10  $\mu$ l) of conditioned media were analyzed for proteinase activity by substrate gel




Figure 2. RT-PCR (A), Western blot analysis (B) and zymography (C) of MMP-2 expression and activity in ovarian cancer cells transfected with VEGF<sub>165</sub> cDNA or treated with anti-VEGF antibody, with IgG as a control. Up-regulation of MMP-2 expression was detected in both CaOV3 and CoC1 cells transfected with VEGF<sub>165</sub> cDNA. Specific VEGF antibody treatment down-regulates the expression of MMP-2 in both CaOV3 and CoC1 cells.

zymography as described previously. Briefly, equal amounts of proteins were separated in 10% SDS-PAGE co-polymerized with 0.1% gelatin. After electrophoresis, the gels were rinsed twice in 2.5% Triton X-100 for 30 min at room temperature, then incubated at 37°C for 20 h in 1.5 M NaCl, 50 mM Tris-Cl, and 10 mM CaCl<sub>2</sub> (pH 7.5). The gels were stained with 0.5% Coomassie blue R250 and destained in 50% methanol and 10% acetic acid in H<sub>2</sub>O (21).

**In vitro invasion assay.** *In vitro* invasion assay was performed according to a published protocol with some modifications (22). Invasion was measured using 48-well units with 8 μm porosity polycarbonate filters. The upper side of the filter was coated with Matrigel matrix 120 μg/well, incubated at 37°C for 3 h and left to dry at room temperature overnight. The Matrigel matrix was rehydrated with 100 μl of pre-warmed DMEM for 2 h at room temperature. Cells were harvested, washed and suspended in DMEM in the absence or presence of 50 nM VEGF mAb at 7.5x10<sup>3</sup>/well. The lower chambers were filled with serum-free conditioned media of NIH 3T3. Noncoated membrane inserts served as controls in the invasion assay. Following incubation for 18 h at 37°C under standard culture conditions, noninvasive cells were removed from the upper surface of the membrane, followed by fixation with 70% methanol at room temperature for 45 min and stained with hematoxylin. All experiments were completed in triplicate, and at least 10 fields were counted.

**Image and statistical analysis.** Photographs were scanned, and the intensity of bands with background subtractions was measured using Leica Q550 IW Image Analysis software. The expression of VEGF and MMP-2 was indirectly reflected by the ratio of β-actin level. All experiments were repeated at least 3 times, and all results were expressed as means ± SEM, and assessed using the unpaired two-tailed Student's t-test (p-values <0.05 were considered significant).

## Results

**VEGF expression in stably transfected ovarian tumor cell lines.** To determine the role of VEGF overexpression in tumor progression, both CaOV3 and CoC1 cells were transfected with VEGF<sub>165</sub> cDNA. RT-PCR analysis of total RNA from subconfluent culture cells showed a significant increase of VEGF expression in CaOV3 and CoC1 cell lines after transfection (CaOV3/PcDNA-VEGF 0.98±0.05 vs. control 0.84±0.03, p<0.05; CoC1/PcDNA-VEGF 0.87±0.06 vs. control 0.62±0.04, p<0.05) (Fig. 1A). This modulation of VEGF expression was confirmed by measuring the VEGF protein using Western blot analysis. As shown in Fig. 1B, the level of VEGF protein in conditioned media was in accordance with the expression of VEGF mRNA in tumor cells (CaOV3/PcDNA-VEGF 24.4±1.2 vs. control 18.3±0.7, p<0.05; CoC1/PcDNA-VEGF 20.8±0.8 vs. control 15.8±0.6, p<0.05).

**Overexpression of VEGF enhances the production and activity of MMP-2.** To determine how VEGF promotes ovarian cancer cell invasion, several experiments were performed to study the effect of VEGF on production of MMP-2 protease secreted by tumor cells, which could degrade the Matrigel matrix for invasion through this physical barrier filter. As assessed by RT-PCR and Western blot analysis, the expression of MMP-2 mRNA and protein increased simultaneously in both CaOV3 and CoC1 cells transfected with VEGF<sub>165</sub> cDNA (Fig. 2A and B). We then screened the change of extracellular matrix-degrading proteinase activities. Conditioned media from ovarian tumor cells were tested for MMP-2 activity using zymography. Regions of proteolytic activity were visualized as clear zones against a blue background. The increased expression of MMP-2 mRNA and protein correlated with enhanced collagenase activity. The MMP-2 activities of transfected CaOV3 and CoC1 cells were detected as 25.3±1.2 and 18.9±0.9, respectively, while only 19.3±0.8 and 9.8±0.5 were found in nontransfected cells (Fig. 2C). There was a significant difference between VEGF<sub>165</sub> cDNA-transfected cells and nontransfected cells (p<0.05). The study showed that VEGF transfection increased both production and activity of MMP-2 in ovarian cancer cells.

**VEGF overexpression correlates with tumor invasion in vitro.** To further investigate the role of VEGF in tumor cell invasion, a modified Boyden chamber assay was used to test tumor cell invasion *in vitro*. The invasive activity was determined by measuring the ability of tumor cells to migrate through Matrigel-coated filters. We found that the VEGF<sub>165</sub> cDNA-transfected cells showed VEGF overexpression and had high invasive activity *in vitro*, whereas the non-transfected cells displayed low levels of VEGF expression and had poor ability to traverse the Matrigel barrier. The mean percentage of transfected tumor cells was higher than that of nontransfected cells (CaOV3/PcDNA-VEGF 42.5±4.1 vs. control 24.7±1.9, p<0.05; CoC1/PcDNA-VEGF 26.8±2.4 vs. control 8.6±1.1, p<0.05) (Fig. 3 and Table I). Overall, a 2- to 4-fold increase of invasive activity was induced in VEGF<sub>165</sub> cDNA-transfected cells when compared with






Figure 3. Invasion assays were carried out in the Matrigel-coated membrane inserts. Noncoated membrane inserts were seeded to serve as controls. The obvious ability of traversing the Matrigel-coated membrane was detected in VEGF<sub>165</sub> cDNA-transfected CaOV3 (A) and CoC1 ovarian cancer cells when compared to nontransfected cells or empty vector-transfected cells. Data are expressed as the percentage of invasion, the ratio of cells invading through the Matrigel matrix-coated inserts compared to uncoated control inserts.

nontransfected cells. These results demonstrated that VEGF played an important role in ovarian cancer cell invasion. VEGF may promote ovarian cancer cells to secrete MMP-2 protease, which accelerates tumor cell invasion by degrading the extracellular matrix.

*Effect of anti-VEGF antibody administration on expression and activity of MMP-2 invasiveness of ovarian cancer cells in vitro.* Previous reports demonstrated that a monoclonal antibody against VEGF inhibited S.C. tumor formation in a dose- and time-dependent manner and reduced the number and size of liver metastases (23). To confirm that VEGF

expression and MMP-2 activity are functionally associated, anti-VEGF monoclonal IgG was administered with CaOV3 and CoC1 ovarian cancer cells. We found that antibody treatment reduced the expression and activity of MMP-2 (Fig. 2). These findings suggested that VEGF expression and MMP-2 activity are physiologically linked in ovarian tumor cells. Accordingly, *in vitro* invasion of the two cell lines was reduced significantly when treated with anti-VEGF monoclonal antibody (CaOV3/VEGF-Ab  $24.7 \pm 1.9$  vs. control  $10.2 \pm 0.7$ ; CoC1/VEGF-Ab  $8.6 \pm 1.1$  vs. control  $5.4 \pm 0.3$ ) (Fig. 3 and Table I).

## Discussion

There is evidence of a relationship between VEGF and MMPs in tumor progression. Herein we showed that VEGF induced the release of biologically active MMP-2 in the culture medium of ovarian tumor cells. This was associated with tumor invasion, providing direct evidence that VEGF is associated with the release of MMP-2 by ovarian tumor cells (24).

Vascular endothelial growth factor is a multifunctional polypeptide growth factor that plays an important role in tumor angiogenesis and invasion. Previously it has been indicated that there is a correlation between the expression of VEGF and tumor cell migration and invasion (27,28). In serous ovarian cystadenocarcinomas, VEGF expression was associated with its malignant behavior (6,25,26). However, no direct evidence has been provided as to how VEGF is responsible for promoting ovarian tumor metastasis. In the current study, we transfected VEGF<sub>165</sub> cDNA into ovarian cancer cells to regulate the expression of VEGF. The data showed that endogenous VEGF mRNA and protein levels increased interdependently in cultured cells after being transfected. In line with previous data showing that human squamous cell carcinomas SCC-13 transfected with VEGF164 in the sense (SCC/VEGF+) vector invaded the surrounding tissue (29), we found there was an obvious enhancement *in vitro* invasiveness through Matrigel-coated filters in VEGF-transfected CaOV3 and CoC1 cells compared with nontransfected groups. Furthermore, the invasion ability of tumor cells was reduced after receiving VEGF monoclonal antibody administration in our study. This finding suggests that VEGF itself has a critical role in the regulation of ovarian tumor invasion.

Proteolysis may be another important factor for ovarian cancer metastasis (13-15). One family of proteases, MMPs, could be influenced at the transcriptional level by several different factors, including hormones, growth factors,

Table I. *In vitro* invasion ability of ovarian cancer cells (%).

Cell line	Tranfects or treatments				
	Control	PcDNA3.1	PcDNA-VEGF	VEGF-Ab	IgG
CaOV3	24.7±1.9	26.6±2.1	42.5±4.1 <sup>a</sup>	10.2±0.7 <sup>a</sup>	21.5±2.3
CoC1	8.6±1.1	7.9±1.4	26.8±2.4 <sup>a</sup>	5.4±0.3 <sup>a</sup>	9.4±1.2

<sup>a</sup>p<0.05 compared with control.

oncogenes and cytokines. Some reports suggest that there is interaction between VEGF and MMP expression. It was demonstrated that VEGF increased the release of gelatinase A in microvascular endothelial cells *in vitro*, and up-regulated MMP-2 expression in brain tumor cells (30,31). In ovarian cancer, the MMP-VEGF relationship is indicated by several observations. Huang *et al*, using *in vivo* models of ovarian carcinoma, found an important role for macrophage-derived MMP-9 in angiogenesis and ovarian tumor growth (15). However, a functional association between VEGF expression and the activity of MMP-2 has not been demonstrated.

The present study showed that the expression and activity of MMP-2 were increased after VEGF stimulation. There may be several possible mechanisms of action of VEGF, including directly stimulating MMP-2 release from tumor cells, and activating other factors involved in MMP-2 release. Additional studies are necessary to clarify this phenomenon. It should be noted that VEGF stimulates the expression of interstitial collagenase at the mRNA and protein levels in human umbilical vein endothelial cells, but no induction was seen in the expression of other MMP members, including MMP-2 (32,33). The differences may come from the cell and tissue specification or interaction with MMPs and their inhibitors the TIMPs. We also found that the induction of MMP-2 by VEGF cDNA transfection in the two ovarian cancer cell lines correlated with great invasive potential. An inhibition of VEGF activity with a neutralizing antibody significantly decreased invasion in both cell lines. Therefore, our results suggested that VEGF could play an important role in invasion processes through the induction of proteolytic response in tumor cells expressing MMP-2.

In conclusion, our results suggested that the overexpression of VEGF correlated with the *in vitro* invasiveness of ovarian cancer cells. Induction and activity of MMP-2 stimulated by VEGF could be the main mechanism by which VEGF gives impetus to the invasion of ovarian cancer cells. Our results emphasized the importance of induction of MMP-2 by VEGF during tumor metastasis, and VEGF may constitute a novel therapeutic target for antiangiogenic cancer therapy.

## Acknowledgements

This work was sponsored by grants from the National Science Foundation of China (no. 30025017) and '973' Program of China (no. 2002CB513100).

## References

- Lee JC, Chow NH, Wang ST and Huang SM: Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. *Eur J Cancer* 36: 748-753, 2000.
- Shih CH, Ozawa S, Ando N, Ueda M and Kitajima M: Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. *Clin Cancer Res* 6: 1161-1168, 2000.
- Shang ZJ, Li JR and Li ZB: Circulating levels of vascular endothelial growth factor in patients with oral squamous cell carcinoma. *Int J Oral Maxillofac Surg* 31: 495-498, 2002.
- Linderholm BK, Lindh B, Beckman L, *et al*: Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers. *Clin Breast Cancer* 4: 340-347, 2003.
- Qi SY: Expression of vascular endothelial growth factor and microvessel density in ovarian tumor. *Ai Zheng* 229: 320-323, 2003.
- Brustmann H and Naude S: Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage. *Gynecol Oncol* 84: 47-52, 2002.
- Duyndam MC, Hilhorst MC, Schluper HM, *et al*: Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts. *Am J Pathol* 160: 537-548, 2002.
- Ma D, Gerard RD, Li XY, Alizadeh H and Niederkorn JY: Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model. *Blood* 90: 2738-2746, 1997.
- Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM and Shafie S: Metastasis potential correlates with enzymatic degradation of basement membrane collagen. *Nature* 284: 67-68, 1980.
- Shimada T, Nakamura H, Yamashita K, *et al*: Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human oral squamous cell carcinomas: implications for lymph node metastasis. *Clin Exp Metastasis* 18: 179-188, 2000.
- Kawata R, Shimada T, Maruyama S, Hisa Y, Takenaka H and Murakami Y: Enhanced production of matrix metalloproteinase-2 in human head and neck carcinomas is correlated with lymph node metastasis. *Acta Otolaryngol* 122: 101-106, 2002.
- Moore DH, Allison B, Look KY, Sutton GP and Bigsby RM: Collagenase expression in ovarian cancer cell lines. *Gynecol Oncol* 65: 78-82, 1997.
- Sakata K, Shigemasa K, Uebaba Y, Nagai N and Ohama K: Expression of matrix metalloproteinases-2 and -9 by cells isolated from the peritoneal fluid of women with ovarian carcinoma. *Acta Cytol* 46: 697-703, 2002.
- Schmalfeldt B, Prechtel D, Harting K, *et al*: Increased expression of matrix metalloproteinases MMP-2, MMP-9 and the urokinase type plasminogen activator is associated with progression from benign to advanced ovarian cancer. *Clin Cancer Res* 7: 2396-2404, 2001.
- Huang S, Van Arsdall M, Tedjarati S, McCarty M, Wu W, Langley R and Fidler IJ: Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. *J Natl Cancer Inst* 94: 1134-1142, 2002.
- Wang H and Keiser JA: Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1. *Circ Res* 83: 832-840, 1998.
- Yao JS, Chen Y, Zhai W, Xu K, Young WL and Yang GY: Minocycline exerts multiple inhibitory effects on vascular endothelial growth factor-induced smooth muscle cell migration. *Circ Res* 95: 364-371, 2004.
- Harada H, Nakagawa K and Iwata S: Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. *Cancer Res* 59: 3783-3789, 1999.
- Hofmann UB, Westphal JR, Van Kraats AA, Ruiter DJ and Van Muijen GN: Expression of integrin  $\alpha\beta 3$  correlation with activation of membrane-type matrix metalloproteinase-1 (MT1-mmp) and matrix metalloproteinase-2 (mmp-2) in human melanoma cells *in vitro* and *in vivo*. *Int J Cancer* 87: 12-19, 2000.
- Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE and Schror K: Cyclooxygenase-2 expression in human esophageal carcinoma. *Cancer Res* 59: 198-204, 1999.
- Reddy KB, Krueger JS, Kondapaka SB and Diglio CA: Mitogen-activated protein kinase regulates the expression of proteinase B (MMP-9) in breast epithelial cells. *Int J Cancer* 82: 268-273, 1999.
- O'Charoenrat P, Rhys-Evans P, Modjtahedi H, Court W, Box G and Eccles S: Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinases-9 expression and *in vitro* invasion. *Int J Cancer* 86: 307-317, 2000.
- Warren RS, Yuan H, Matli MR, Gillett NA and Ferrara N: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. *J Clin Invest* 95: 1789-1797, 1995.
- Rodriguez GC, Haisley C, Hurteau J, Moser TL, Whitaker R, Bast RC Jr and Stack MS: Regulation of invasion of epithelial ovarian cancer by transforming growth factor- $\beta$ . *Gynecol Oncol* 80: 245-253, 2001.

25. Dvorak HF, Brown LF, Detmar M and Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. *Am J Pathol* 46: 1029-1039, 1995.
26. Oehler MK and Caffier H: Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer. *Anticancer Res* 20: 5109-5112, 2000.
27. Schuch G, Heymach JV, Nomi M, *et al*: Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. *Cancer Res* 63: 8345-8350, 2003.
28. Hayashibara T, Yamada Y, Miyanishi T, *et al*: Vascular endothelial growth factor and cellular chemotaxis: a possible autocrine pathway in adult T cell leukemia cell invasion. *Clin Cancer Res* 7: 2719-2726, 2001.
29. Ueda M, Terai Y, Kumagai K, Ueki K, Yamaguchi H, Akise D and Ueki M: Vascular endothelial growth factor C gene expression is closely related to invasion phenotype in gynecological tumor cells. *Gynecol Oncol* 82: 162-166, 2001.
30. Lamoreaux WJ, Fitzgerald MC, Reiner A, Hasty KA and Charles ST: Vascular endothelial growth factor increases release of gelatinaseA and decrease release of tissue inhibitors of metalloproteinases by microvascular endothelial cells *in vitro*. *Microvasc Res* 55: 29-42, 1998.
31. Rooprai HK, Rucklidge GJ, Panou C and Pilkington GJ: The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumor cells. *Br J Cancer* 82: 52-55, 2000.
32. Unemori EN, Ferrara N, Bauer EA and Amento EP: Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. *J Cell Physiol* 153: 557-562, 1992.
33. Hesling C, D'Incan M, Mansard S, *et al*: *In vivo* and *in situ* modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases. *Br J Dermatol* 150: 761-767, 2004.